dc.contributor.author | Kılıçkap, Saadettin | |
dc.contributor.author | Buğdaycı Basal, Fatma | |
dc.contributor.author | Demirkazık, Ahmet | |
dc.contributor.author | Gürsoy, Pınar | |
dc.contributor.author | Demirci, Ufuk | |
dc.contributor.author | Erman, Mustafa | |
dc.contributor.author | Yumuk, Fulden | |
dc.contributor.author | Çay Şenler, Filiz | |
dc.contributor.author | Çakar, Burcu | |
dc.contributor.author | Çiçin, İrfan | |
dc.contributor.author | Öztürk, Akın | |
dc.contributor.author | Coşkun, Hasan Şenol | |
dc.contributor.author | Çubukçu, Erdem | |
dc.contributor.author | Işıkdoğan, Abdurrahman | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Tatlı, Ali Murat | |
dc.contributor.author | Karaağaç, Mehmet Onur | |
dc.contributor.author | Sakalar, Teoman | |
dc.contributor.author | Eralp, Yeşim | |
dc.contributor.author | Korkmaz, Taner | |
dc.date.accessioned | 2019-12-24T12:15:18Z | |
dc.date.available | 2019-12-24T12:15:18Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Kılıçkap, S., Buğdaycı Basal, F., Demirkazık, A., Gürsoy, P., Demirci, U., Erman, M. ... Korkmaz, T. (2019). Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?44th Congress of the European-Society-for-Medical-Oncology (ESMO) içinde (637-637. ss.). Barcelona, Spain, September 27-October 01, 2019. | en_US |
dc.identifier.issn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/4651 | |
dc.description | Conference
Conference: 44th Congress of the European-Society-for-Medical-Oncology (ESMO)
Location: Barcelona, SPAIN
Date: SEP 27-OCT 01, 2019
Sponsor(s):European Soc Med Oncol; Japanese Soc Med Oncol | en_US |
dc.description.abstract | Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who have Ple-I/E. Methods: In this multicenter study, patients with ALKþ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALKþpatients with NSCLC. Results: Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p¼0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p¼0.541). The rate of smokers was 43.4% (n¼157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p¼0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALKþpatients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p¼0.008; 19.1% vs 4.8%, p¼0.002; 20.6% vs 8.9%, p¼0.003). The median PFS was longer in ALKþ patients who have Ple-I/E 18.7 vs 10.6 months, p¼0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALKþpatients who have pleural involvement/infusion 44.6 vs 22.6 months, p¼0.051). The 1-, 2- and 3- year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement. Conclusions: Brain, liver and bone metastases are lower in ALKþpatients with Ple-I/E. Presentation with Ple-I/E in patients with ALKþ NSCLC is associated with longer overall and progression-free survival. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. | en_US |
dc.description.sponsorship | European Society for Medical Oncology | en_US |
dc.description.sponsorship | Japanese Society of Medical Oncology | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Oxford University Press | en_US |
dc.rights | info:eu-repo/semantics/restrictedAccess | en_US |
dc.subject | ALK-Positive | en_US |
dc.subject | Effusion | en_US |
dc.subject | Prognostic Significance | en_US |
dc.title | Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC? | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | 44th Congress of the European-Society-for-Medical-Oncology (ESMO) | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 30 | en_US |
dc.identifier.issue | Supplement: 5 | en_US |
dc.identifier.startpage | 637 | en_US |
dc.identifier.endpage | 637 | en_US |
dc.relation.ec | 0923-7534 | |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q1 | en_US |